CB2 Gene Expression, Genetics, and Depression
Source: Onaivi et al., PLoS ONE 3(2): e1640
Difficulty: Advanced | Prerequisites: Basic neuropharmacology, endocannabinoid system overview, molecular biology techniques (RT-PCR, Western blot, immunohistochemistry). Familiarity with receptor pharmacology and behavioural models of depression is helpful.
The endocannabinoid system has two main receptors: CB1 and CB2. For years, textbooks taught that CB1 receptors live in the brain and CB2 receptors belong to the immune system. This paper challenged that orthodoxy by demonstrating functional CB2 receptor expression in neurons of the rodent brain, and linking a CB2 gene polymorphism to depression in humans. The work sits at the intersection of neuropharmacology, psychiatric genetics, and addiction biology, and it matters because CB2 receptors, if confirmed as functional in the CNS, could become drug targets for depression and substance abuse without the psychoactive side effects associated with CB1-targeted therapies.
CB2 cannabinoid receptors are not just immune system receptors. They are expressed in brain neurons, their gene expression changes with stress and drug exposure, and a specific genetic variant (Q63R polymorphism) is significantly associated with major depression in a Japanese population. This opens the door to CB2-targeted treatments for depression and addiction.
CB2 receptor (CB2-R)
A G protein-coupled cannabinoid receptor encoded by the CNR2 gene. Originally classified as a "peripheral" cannabinoid receptor found predominantly in immune cells (spleen, tonsils, thymus). Now demonstrated to also be expressed in brain neurons.
In simple terms, this is the second cannabinoid receptor. It was long thought to exist only outside the brain, but this study shows it is also present in brain tissue.
CB1 receptor (CB1-R)
The primary cannabinoid receptor in the central nervous system. CB1-Rs are mainly presynaptic and mediate most of the psychoactive effects of cannabis. Expression levels of CB1 are roughly 100 times higher than CB2 in the brain.
Think of CB1 as the "well-known" brain cannabinoid receptor, the one responsible for the high from cannabis.
Endocannabinoid physiological control system (EPCS)
The body's own cannabinoid signalling network, comprising endogenous ligands (e.g. anandamide, 2-AG), their receptors (CB1, CB2), and the enzymes that synthesise and degrade them.
In simple terms, this is your body's built-in cannabis-like signalling system.
Q63R polymorphism
A non-synonymous single nucleotide polymorphism in the CB2 gene at cDNA position 188-189, resulting in a dinucleotide conversion (AA to GG) that substitutes glutamine (Q) with arginine (R) at amino acid position 63. This is a missense mutation with functional consequences for the CB2 receptor protein.
Think of it as a spelling change in the CB2 gene that swaps one amino acid for another, altering how the receptor works.
Chronic mild stress (CMS) model
A validated rodent model of depression in which animals are exposed to a series of unpredictable, mild stressors (cage tilt, damp bedding, food/water deprivation, stroboscopic illumination) over several weeks. The key endpoint is anhedonia, measured by reduced sucrose consumption.
In simple terms, this is the standard lab method for making mice "depressed" by subjecting them to weeks of low-level, unpredictable stress.
Anhedonia
A core symptom of major depression defined as the inability to experience pleasure from activities normally found enjoyable. In rodent models, it is operationally defined as reduced preference for sucrose solution.
Think of it as losing the ability to enjoy things you normally like. In mice, it is measured by how much sugar water they drink.
JWH015
A putative CB2 receptor agonist (activator) used as a pharmacological tool in this study. It reduces locomotor activity and increases anxiety-like behaviour at higher doses.
In simple terms, this is a drug that switches on CB2 receptors.
SR144528
A selective CB2 receptor antagonist (blocker). Used to confirm that behavioural effects are mediated through CB2 receptors.
In simple terms, this drug blocks CB2 receptors from being activated.
AM630
Another CB2 receptor antagonist used in this study, particularly in the alcohol consumption and anhedonia experiments.
In-situ hybridisation
A molecular biology technique that uses labelled complementary RNA or DNA probes to detect specific mRNA sequences in tissue sections. Used here to confirm CB2 gene expression in the cerebellum of wild-type mice (and its absence in CB2 knockout mice).
Think of it as a method for finding where a gene is being read (transcribed) inside a slice of brain tissue.
Immunohistochemistry (IHC)
A technique using antibodies to detect specific proteins in tissue sections. Used here to map CB2-R protein distribution in mouse and rat brain.
Western blotting
A laboratory method for detecting specific proteins in a tissue sample by separating them by size on a gel, transferring to a membrane, and probing with antibodies. Used here to confirm CB2-R protein expression (major band at approximately 53 kDa).
CB2 receptors were historically classified as "peripheral" receptors, restricted to immune cells (spleen, tonsils, macrophages)
Multiple laboratories failed to detect CB2-Rs in healthy brain tissue, reinforcing this view
CB2-R expression had been demonstrated in rat microglial cells and brain-associated cells during inflammation, but neuronal expression remained controversial
This study (Onaivi et al., 2008) provided converging evidence from multiple techniques that CB2-Rs are functionally expressed in brain neurons:
RT-PCR confirmed CB2 gene transcripts in whole brain and specific regions (striatum, midbrain, hippocampus)
Western blotting revealed a major CB2-R protein band at approximately 53 kDa (with additional bands at 37 kDa and 75 kDa)
Immunohistochemistry showed CB2-R immunoreactivity in pyramidal neurons of the cerebral cortex, hippocampal allocortex, corpus callosum, and interneurons
In-situ hybridisation confirmed CB2 mRNA in the cerebellum of wild-type mice but not in CB2 knockout mice
Electron microscopy revealed CB2-Rs localised mainly to post-synaptic elements (dendrites and cell bodies), particularly near the plasma membrane and close to axon terminal contact sites
CB2 expression in the brain is much lower than CB1 (approximately 100-fold less by RT-PCR), which partly explains why it was so difficult to detect
The spleen remains the tissue with the most abundant CB2 expression and was used as a positive control throughout
CB2 gene is expressed in whole brain preparations of both control and chronically stressed mice (CMS model)
CB2 expression was confirmed in specific brain regions: striatum, midbrain, and hippocampus of C57BL/6J mice
CMS exposure did not eliminate CB2 expression but modulated it, and CB2-R protein was enhanced following CMS and prenatal capsaicin exposure (shown by Western blot)
Stress modulates CB2-R expression, suggesting the receptor plays a regulatory role in the brain's stress response
The CMS model produces anhedonia (reduced sucrose consumption), one of the core validated endpoints for modelling depression in rodents
CB2 gene expression changes were also observed across different mouse strains (C57BL/6J and BALBc), indicating the effect is not strain-specific
The CB2 gene has two known non-synonymous polymorphisms: Q63R and H316Y
Structural analysis (Chou-Fasman, Robson methods) predicted that only Q63R (not H316Y) causes a structural change in the CB2 protein, so the study focused on Q63R
Q63R is a missense polymorphism at cDNA position 188-189:
A dinucleotide conversion from AA to GG
This predicts a non-conservative amino acid substitution: glutamine (Q) replaced by arginine (R) at position 63
Humans normally have glutamine at position 63; mice and rats have arginine
Study population: 166 Japanese patients with major depression (DSM-IIIR criteria, bipolar excluded) vs 487 age- and gender-matched healthy controls
Key genetic findings:
Significant association between Q63R polymorphism and depression (p = 0.007, odds ratio 1.42, 95% CI: 1.09 to 1.83)
The RR genotype was significantly overrepresented in depressed subjects (39%) compared to controls (30%)
RR genotype vs RQ+QQ: p = 0.01, odds ratio 1.95, 95% CI: 1.11 to 3.44
The Q63R polymorphism had previously been linked to osteoporosis and autoimmune disorders
Previous in-vitro work showed a functional difference for the RR genotype in lymphocyte assays, confirming this is not a silent variant
The study was conducted in a Japanese population; whether these findings generalise to other ethnicities remains an open question
RT-PCR (TaqMan real-time PCR): Used to quantify CB2 gene expression in whole brain and dissected regions. Spleen served as positive control (highest CB2 expression). GAPDH and beta-actin were used for normalisation. Control brain samples set at 1.0.
Western blotting: Confirmed CB2-R protein presence. Major band at approximately 53 kDa; additional bands at 37 and 75 kDa. Specificity confirmed by pre-adsorption with immunising peptide (signal disappeared when antibody was blocked with the CB2 peptide).
Immunohistochemistry (IHC): Mapped CB2-R protein distribution in brain sections. Three commercial CB2-R antibodies were tested for specificity. CB2-R immunoreactivity was detected in cerebral cortex (pyramidal neurons), hippocampus, corpus callosum, and interneurons. Additional validation: CB2-R immunoreactivity was absent in global CB2-R knockout mice.
In-situ hybridisation: Used biotin-labelled RNA probes (sense and antisense). CB2 mRNA detected in the cerebellum of wild-type mice but not in CB2 knockout mice. Sense controls showed no signal in wild-type, confirming probe specificity.
Immunoelectron microscopy: The highest-resolution technique used. Showed CB2-R immunoreactivity mainly on post-synaptic elements (dendrites near the plasma membrane, close to axon terminal contacts). Some dendrites received multiple synaptic contacts from axon terminals that lacked CB2-R labelling. Pattern suggests excitatory, possibly glutamatergic synapses.
Antibody specificity controls used throughout:
Pre-adsorption of CB2 antibody with the immunising peptide
CB2-R knockout mice as negative controls
Sense probes for in-situ hybridisation
Two different CB2 antibody types showing consistent staining patterns
Odds ratio calculation: OR = 1.42 for allelic comparison of Q63R polymorphism (depressed vs controls). OR = 1.95 for RR genotype vs RQ+QQ genotypes.
CB2 gene expression quantification: Relative expression calculated using the comparative Ct method (delta-delta Ct), referenced to the ABI Prism 7700 User Bulletin #2. Control brain samples normalised to 1.0 with GAPDH as endogenous control.
Key figure references from the paper:
Figure 1: CB2 gene expression across brain regions, strains, drug treatments, and alcohol preference
Figure 2: Western blots, RFLP genotyping gels, and in-situ hybridisation images
Figure 4: Immunohistochemistry showing CB2-R in cortex, hippocampus, and corpus callosum
Figure 8: Electron micrographs showing post-synaptic CB2-R localisation in hippocampus
If CB2 receptors are functional drug targets in the brain, they could offer a route to treating depression and addiction without the psychoactive side effects that come with targeting CB1 receptors. This is clinically significant because CB1-targeted therapies (like rimonabant, withdrawn from the market) caused psychiatric adverse effects. A selective CB2-R approach might bypass these problems entirely, offering analgesic, antidepressant, or anti-addictive effects through a receptor that does not produce a "high."
Students often assume CB2 receptors are found only in immune cells. They are not. This study and others have now confirmed neuronal CB2-R expression in brain, though at much lower levels than CB1.
Students sometimes confuse CB1 and CB2 receptor localisation. CB1 is mainly presynaptic; CB2 appears to be mainly post-synaptic (on dendrites and cell bodies).
A common error is to think that the Q63R polymorphism is a rare mutation. It is a common polymorphism with a measurable allele frequency in the general population (the R allele frequency was 0.565 in controls and 0.648 in depressed subjects in this study).
Students may believe that "knockout mouse" results automatically translate to human physiology. The human and rodent CB2 genes differ at position 63 (humans have glutamine, rodents have arginine), so species differences are important when interpreting these findings.
⚠️ Know the difference between CB1 and CB2 receptor distribution: CB1 is predominantly in the brain (presynaptic), CB2 was thought to be peripheral/immune only but is now confirmed in brain neurons (mainly post-synaptic).
⚠️ The Q63R polymorphism statistics are likely testable: p = 0.007, OR = 1.42 for allelic association; p = 0.01, OR = 1.95 for the RR genotype. Understand what an odds ratio greater than 1 means here (increased risk).
⚠️ Be able to explain why multiple detection methods were needed: each technique (RT-PCR, Western blot, IHC, in-situ hybridisation, electron microscopy) addresses a different level of evidence, from gene expression to protein localisation to subcellular positioning.
⚠️ Understand why antibody specificity controls matter: pre-adsorption with immunising peptide, knockout mice as negative controls, and sense probes for hybridisation. These are standard questions on methods sections.
True or false: CB2 receptors are expressed exclusively in immune cells. _____ (False)
The Q63R polymorphism in the CB2 gene involves a substitution of _______ by _______ at position 63. (glutamine; arginine)
True or false: CB2-R expression in the brain is at similar levels to CB1-R expression. _____ (False, CB2 is approximately 100-fold lower)
In the CMS model of depression, anhedonia is measured by reduced consumption of _______. (sucrose solution)
True or false: The subcellular localisation of CB2-Rs in the brain is mainly presynaptic. _____ (False, mainly post-synaptic)
Q: What evidence supports the presence of functional CB2 receptors in brain neurons, as opposed to immune or glial cells only?
A: Multiple converging lines of evidence: (1) RT-PCR detected CB2 gene transcripts in whole brain and specific regions (striatum, midbrain, hippocampus); (2) Western blotting confirmed CB2-R protein at approximately 53 kDa; (3) immunohistochemistry showed CB2-R immunoreactivity in pyramidal neurons of the cortex and hippocampus; (4) in-situ hybridisation detected CB2 mRNA in cerebellum of wild-type but not knockout mice; (5) electron microscopy localised CB2-Rs to post-synaptic elements (dendrites). Antibody specificity was confirmed by pre-adsorption controls and knockout mouse comparisons.
Q: Describe the Q63R polymorphism in the CB2 gene and its association with depression.
A: Q63R is a missense polymorphism at cDNA position 188-189 involving a dinucleotide conversion (AA to GG) that substitutes glutamine with arginine at amino acid position 63. In a Japanese population study (166 depressed patients vs 487 controls), the R allele was significantly more frequent in depressed subjects (allelic comparison: p = 0.007, OR = 1.42). The RR genotype was also significantly associated with depression (p = 0.01, OR = 1.95), consistent with a recessive model for the R allele.
Q: Why was the CMS model chosen for studying CB2-R involvement in depression, and what is its key endpoint?
A: The chronic mild stress model is a validated rodent model of depression that produces anhedonia, a core symptom of major depression. Anhedonia is measured as reduced sucrose consumption compared to unstressed controls. The CMS model was chosen because it mimics the chronic, low-grade stress associated with human depression, and anhedonia is clinically relevant (it corresponds to loss of pleasure in depressed patients).
Q: How does CB2-R subcellular localisation differ from CB1-R localisation, and what are the implications?
A: CB1-Rs are mainly presynaptic in the CNS, where they act as retrograde messengers regulating synaptic transmission. CB2-Rs, based on electron microscopy data, are mainly post-synaptic, localised to dendrites and cell bodies near the plasma membrane. This suggests CB2 and CB1 receptors may regulate neuronal activity through different mechanisms, possibly working independently or cooperatively in different neuronal populations.
This material connects directly to the broader endocannabinoid system, which is typically covered earlier in neuropharmacology courses. Understanding CB1-R pharmacology (including the failed CB1 antagonist rimonabant for obesity) provides context for why CB2-R targeting is attractive. The genetics component (Q63R polymorphism, odds ratios, Hardy-Weinberg equilibrium) ties into pharmacogenomics and psychiatric genetics. The CMS model and anhedonia concept link to clinical psychiatry and the neurobiology of depression, particularly the monoamine hypothesis and its limitations.
CB2 receptor, CNR2 gene, cannabinoid receptor type 2, brain CB2, neuronal CB2, CB2-R, CB1 vs CB2, endocannabinoid system, EPCS, Q63R polymorphism, CB2 Q63R, CB2 polymorphism depression, chronic mild stress model, CMS, anhedonia, sucrose preference test, JWH015, SR144528, AM630, CB2 agonist, CB2 antagonist, immunohistochemistry brain CB2, Western blot CB2, in-situ hybridisation CB2, electron microscopy cannabinoid receptor, post-synaptic CB2, CB2 knockout mouse, cannabis depression, endocannabinoid depression, cannabinoid pharmacogenomics, CB2 substance abuse